Literature DB >> 20117150

The oncofetal H19 RNA connection: hypoxia, p53 and cancer.

Imad J Matouk1, Shaul Mezan, Aya Mizrahi, Patricia Ohana, Rasha Abu-Lail, Yakov Fellig, Nathan Degroot, Eithan Galun, Abraham Hochberg.   

Abstract

Expression of the imprinted H19 gene is remarkably elevated in a large number of human cancers. Recently, we reported that H19 RNA is up-regulated in hypoxic stress and furthermore, it possesses oncogenic properties. However, the underlying mechanism(s) of these phenomena remain(s) unknown. Here we demonstrate a tight correlation between H19 RNA elevation by hypoxia and the status of the p53 tumor suppressor. Wild type p53 (p53(wt)) prevents the induction of H19 upon hypoxia, and upon its reconstitution in p53(null) cells. The last case is accompanied by a decrease in cell viability. The p53 effect is nuclear and seems independent of its tetramerization. Furthermore, using knockdown and over-expression approaches we identified HIF1-alpha as a critical factor that is responsible for H19 induction upon hypoxia. Knocking down HIF1-alpha abolishes H19 RNA induction, while its over-expression significantly enhances the H19 elevation in p53(null) hypoxic cells. In p53(wt) hypoxic cells simultaneous suppression of p53 and over-expression of HIF1-alpha are needed to induce H19 significantly, while each treatment separately resulting in a mild induction, indicating that the molecular mechanism of p53 suppression effect on H19 may at least in part involve interfering with HIF1-alpha activity. In vivo a significant increase in H19 expression occurred in tumors derived from p53(null) cells but not in p53(wt) cells. Taken together, our results indicate that a functional link exists between p53, HIF1-alpha and H19 that determines H19 elevation in hypoxic cancer cells. We suggest that this linkage plays a role in tumor development. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117150     DOI: 10.1016/j.bbamcr.2010.01.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  104 in total

Review 1.  Noncoding RNAs involved in mammary gland development and tumorigenesis: there's a long way to go.

Authors:  Amy N Shore; Jason I Herschkowitz; Jeffrey M Rosen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-03-09       Impact factor: 2.673

2.  Ectopic expressed long non-coding RNA H19 contributes to malignant cell behavior of ovarian cancer.

Authors:  Zhijie Zhu; Ling Song; Jun He; Yanan Sun; Xiaomei Liu; Xiaoyan Zou
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 3.  The evolutionary biology of child health.

Authors:  Bernard Crespi
Journal:  Proc Biol Sci       Date:  2011-02-02       Impact factor: 5.349

4.  Long non-coding RNA H19 enhances cell proliferation and anchorage-independent growth of cervical cancer cell lines.

Authors:  Tawin Iempridee
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

5.  Maternally transmitted foetal H19 variants and associations with birth weight.

Authors:  Clive J Petry; Rachel V Seear; Dianne L Wingate; Carlo L Acerini; Ken K Ong; Ieuan A Hughes; David B Dunger
Journal:  Hum Genet       Date:  2011-05-15       Impact factor: 4.132

Review 6.  Long non-coding RNA functions in lung cancer.

Authors:  Haiwei Sang; Haihong Liu; Peng Xiong; Min Zhu
Journal:  Tumour Biol       Date:  2015-04-21

7.  Association of long noncoding RNA H19 polymorphisms with the susceptibility and clinical features of ischemic stroke in southern Chinese Han population.

Authors:  Jiao Huang; Jialei Yang; Jinhong Li; Zhaoxia Chen; Xiaojing Guo; Siyun Huang; Lian Gu; Li Su
Journal:  Metab Brain Dis       Date:  2019-04-30       Impact factor: 3.584

Review 8.  Emerging roles of long non-coding RNAs in cancer.

Authors:  Manjima Chatterjee; Sonali Sengupta
Journal:  J Biosci       Date:  2019-03       Impact factor: 1.826

Review 9.  Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.

Authors:  Teodora Ribarska; Klaus-Marius Bastian; Annemarie Koch; Wolfgang A Schulz
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

Review 10.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.